Case Study – Oncology

ODC Turned Brazil into the World's #1 Country for a Biomarker-Selected Global Precision Oncology Trial (GIST)

Category: Brazil, Case study, Oncology
Reading Time: < 1 min

Challenge The INSIGHT Phase III trial — evaluating ripretinib vs. sunitinib in advanced GIST — required patients with a highly specific KIT resistance genotype: exon 11 plus secondary exon 17/18 mutations, explicitly excluding exon 9, 13, or 14. With 55 patients enrolled globally across 70 sites in 15 countries, finding eligible patients demanded molecular precision, ctDNA pathway coordination, and active referral follow-up at every step of the funnel.

Strategy

  • Mapping Specialized Oncology Centers: Prioritized sarcoma and GI oncology centers with high-volume advanced GIST patient pools and access to molecular profiling — concentrating prescreening effort where eligible patients could actually be found.
  • Building a Prescreening Engine: ODC activated a systematic country-level tracker, turning passive waiting into active hunting. Site teams reviewed patient databases, flagged post-imatinib progressors, and maintained a structured candidate pipeline.
  • Coordinating the Molecular Pathway: Provided end-to-end support for ctDNA logistics — sample collection, lab coordination, result interpretation — ensuring molecular data arrived within clinically relevant windows and did not delay screening decisions.

Read more by filling out the form below

Results & Why This Matters

  • ~21% of global pre-screenings were generated by Brazil, increasing the main trial recruitment driver – Brazil as the top enrolling country alongside the USA & France.
  • 113 patients were prescreened in Brazil, 10 patients were confirmed eligible, 9 were enrolled, matching France and the United States as the Top enrolling countries.
  • Brazil reduced global dependence on North America and Europe, proving LATAM can function as a peer-level strategic geography in molecularly complex, small-sample-size trials.

INSIGHT Phase III Trial: Ripretinib vs Sunitinib in Advanced GIST KIT Exon 11 + Secondary Exon 17/18 Mutations 

  • 55 patients enrolled globally
  • 15 countries represented
  • 9 patients Enrolled (BR)
  • #1 Tied for Top enroller with USA & France

George S, et al. Future Oncology 2024 – Heinrich M, et al. Nature Medicine 2024 NCT05734105 – Deciphera Pharmaceuticals

Share

Also read

Case study

Case Study – Rare-Disease

ODC Implemented a Three-Pillar Strategy to Unlock LATAM for a Global Ultra-Rare Kidney Disease Trial
Read more
Case study

Case Study – Hematology

ODC Implemented a High-Touch Recruitment Model to Make Brazil a Decisive Late-Stage Accelerator in a Global Rare Hematology Trial
Read more

Sign up for our newsletter for the latest updates

Privacy Notice and Personal Data Processing

By submitting this form, you declare that you are aware that the personal data provided will be processed by ODC Life Sciences to receive, analyze, and respond to your request, make the necessary contacts, and, when applicable, comply with legal or regulatory obligations and exercise ODC’s rights.

When necessary for these purposes, the data may be shared with ODC Group companies and third parties involved in addressing the request, including service providers, partners, sponsors, or research centers, as applicable and in accordance with the principles and requirements set forth in the General Data Protection Law (Brazilian Law No. 13.709/2018 – LGPD).

ODC will adopt appropriate measures to protect the security and confidentiality of personal data and will retain it for the period necessary to fulfill the stated purposes and to comply with legal or regulatory obligations or for the regular exercise of rights.

For more information on the processing of personal data and on exercising the rights provided for in the LGPD (Brazilian General Data Protection Law), please consult the ODC Life Sciences Privacy Policy.

And add a mandatory checkbox for submitting the form, with the following phrase next to the checkbox: I have read and am aware of the Privacy Notice and Personal Data Processing Policy.